ABOS Acumen Pharmaceuticals, Inc. Common Stock
XNAS 2.10 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ABOS
$2.10
—
Key stats
$2.10
- 52-Week Range
- $1.50 – $3.60
- YTD
- +3.96%
- IV Rank (30D)
- 12.15
- Straddle Price
- $1.45
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.2B
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.31% |
| Beta vs SPY | 1.22 |
| Cost of Equity (CAPM) | 12.00% (VRP-adj) |
| WACC | 11.37% |
| Volatility Risk Premium | +228.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -183.4% |
| Book / Price | 42.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.21 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $2.60 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.42 |
| Bollinger Width / SMA20 | 2025.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ALKS, BIIB, DNTH, NBIX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$3.51
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 17.3× · 3 peers |
| Peer P/B | $3.51 | 100% | median 3.9× · 4 peers |
| Peer P/S | n/a | 0% | median 4.3× · 4 peers |
| Market Anchor (SMA50) | $2.60 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-08 · updated
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $0.2B
- Next Earnings
- 2026-11-11 (After-Close)
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -2.89% | 5 |
| Feb | +6.56% | 5 |
| Mar | -20.74% | 5 |
| Apr | -2.69% | 5 |
| May | +0.99% | 5 |
| Jun | +6.26% | 5 |
| Jul | +11.59% | 6 |
| Aug | +3.92% | 6 |
| Sep | +4.63% | 6 |
| Oct | -7.03% | 6 |
| Nov | -15.31% | 5 |
| Dec | +5.68% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.38
SMA 50: $2.60
SMA 200: $2.51
Current: $2.10
EMA 12: $2.21
EMA 26: $2.40
MACD: -0.1853 | Signal: -0.0286
BEARISH
ADX (14): 24.90
WEAK TREND
+DI: 14.23
−DI: 22.60
Momentum Oscillators
RSI (14): 35.70
NEUTRAL
Stoch %K: 10.77
Stoch %D: 9.07
Williams %R: -85.82
Volume & Volatility
BB Upper: $2.96
BB Lower: $1.81
NEUTRAL
OBV: 26,540,112
Vol SMA 20: 600,118
Vol ROC: 90.02%
ATR: $0.18
True Range: $0.11
HV 20: 76.3%
HV 30: 73.6%
HV 60: 68.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-10T00:00:00 – 2026-10-08T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (6/10) - The stock has been range-bound, with no clear trend emerging. Key drivers include positive earnings news and a strong beta, while primary risks are high volatility and the potential for market corrections.
Key Drivers:
- Positive earnings news: Acumen Pharmaceuticals' recent earnings announcements have been well-received by investors.
- Strong beta: The stock's beta of 1.83 indicates it is more volatile than the broader market.
Primary Risks:
- High volatility: The stock has experienced high volatility in recent periods, which may lead to significant price movements.
- Market corrections: A market correction could negatively impact the stock's value if investors become risk-averse.
2-3 Sentence Investment Thesis: ABOS presents a mixed bag for investors. While positive earnings news and a strong beta are attractive, the high volatility and potential for market corrections create uncertainty. A careful evaluation of the stock's technicals and risk metrics is necessary to determine an investment strategy.
Recent News Sentiment Impact: The recent positive earnings news headlines have had a bullish impact on the stock price, with investors responding positively to the company's financial performance.
Technical Analysis
Trend Direction: NEUTRAL (Range-bound)
- Short-term: No clear trend evident
- Medium-term: Range-bound between $2.25 and $2.51
- Long-term: Uptrend from 2025 lows, but consolidation has occurred since then
Support/Resistance Levels:
- Lower Bollinger Band: $1.99 (key support)
- Middle Bollinger Band: $2.25 (resistance)
- Upper Bollinger Band: $2.51 (resistance)
Momentum Signals:
- RSI interpretation: Neutral, with a reading of 56.64
- MACD signal: Bearish crossover, but MACD is still in a neutral zone
- Bollinger Bands position: Squeeze, indicating potential for breakout or mean reversion
News & Sentiment Analysis
Recent Headlines Summary: The past week has seen several positive news headlines from Acumen Pharmaceuticals, including earnings reports and conference participation.
Sentiment Assessment: POSITIVE (75% Positive, 25% Neutral)
Catalyst Identification: Earnings announcements have been the primary catalysts driving the stock price. No major regulatory or product-related events are imminent.
Market Narrative: The recent positive earnings news has aligned with the technical signals, which suggests a bullish trend is developing.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta >1.5)
- Volatility Regime: High volatility regime
- Options Market Signals:
- IV rank: 26.7% (Medium)
- Put/call ratio: Neutral sentiment
- Unusual activity: None notable
Market Context & Positioning
Sector Performance: Healthcare sector has been performing well, with a R-squared correlation of 0.75 to the overall market.
Institutional Activity: No unusual institutional buying or selling patterns are evident.
Correlation Analysis: ABOS has a moderate positive correlation (0.27) with the broader market.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $1.99 (key support)
- Middle Bollinger Band: $2.25 (resistance)
- Upper Bollinger Band: $2.51 (resistance)
Breakout/Breakdown Levels: No clear levels for a breakout or breakdown are evident.
Time-Sensitive Catalysts: Earnings announcements will continue to drive the stock price in the short term.
Risk Management: A stop-loss level of $1.99 would be reasonable, considering the high volatility and potential for market corrections. Position sizing considerations should prioritize risk management to avoid significant losses.
Generated
News
All ABOS news →
Earnings History
8 of 8 under expected move
Avg Expected Move
231.56%
Avg Actual Move
4.43%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-12 | Pre-Market | 58.23% | 16.93% | 0.29x | Within |
| 2025-03-27 | After-Close | 469.51% | 3.25% | 0.01x | Within |
| 2025-05-13 | Pre-Market | 307.41% | 0.09% | 0.00x | Within |
| 2025-08-12 | After-Close | 492.06% | 0.79% | 0.00x | Within |
| 2025-11-12 | Pre-Market | 445.43% | 1.02% | 0.00x | Within |
| 2026-03-26 | After-Close | 25.49% | 11.37% | 0.45x | Within |
| 2026-05-12 | After-Close | 44.35% | 0.40% | 0.01x | Within |
| 2026-08-12 | After-Close | 9.96% | 1.59% | 0.16x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ABOS Options Activity & IV Rank
ABOS IV rank history, 52-week IV rank and IV percentile →
- IV Rank (30D)
- 12.15
- IV Rank (7D)
- 8.67
- IV (30D ATM)
- 135.2%
- Straddle (30D)
- $1.45
- Straddle (7D)
- $0.48
- P/C Volume
- 0.00
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.89
- Correlation (SPY)
- 29.5%
- R²
- 0.09
- Ann. Volatility
- 83.5%
- SPY Volatility
- 13.0%
High volatility - stock moves more than market
Beta & Alpha Over Time
ABOS Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 64,154,568 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$417.59K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $222.68K | 53.32% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $158.60K | 37.98% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $36.31K | 8.70% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
ABOS Insider Trading (Form 4)
Latest: 2026-06-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Derrell Porter | Director | Mixed | −12,800 | $1.86 | -$54.4K | EDGAR |
| 2026-06-10 | Nathan B Fountain | Director | Sell (S) | −6,400 | $2.23 | -$14.3K | EDGAR |
| 2026-06-05 | John A Stalfort III | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | Nathan B Fountain | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | Kimberlee C Drapkin | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | Jeffrey L. Ives | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | Derrell Porter | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | Laura Stoppel | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-06-05 | RA Capital Healthcare Fund LP | Director | Award (A) | +177,500 | — | EDGAR | |
| 2026-06-05 | George Golumbeski | Director | Award (A) | +35,500 | — | EDGAR | |
| 2026-03-18 | Rajeev M. Shah | Director | Award (A) | +30,303,030 | $3.30 | $100.00M | EDGAR |
| 2026-03-10 | Derek M Meisner | Chief Legal Officer & Corp Sec | Mixed | — | $2.55 | -$2.9K | EDGAR |
| 2026-03-03 | Derek M Meisner | Chief Legal Officer & Corp Sec | Mixed | — | $2.43 | -$10.9K | EDGAR |
| 2026-01-28 | Derek M Meisner | Chief Legal Officer & Corp Sec | Mixed | — | $2.43 | -$20.4K | EDGAR |
| 2026-01-23 | Daniel Joseph OConnell | Chief Executive Officer | Sell (S) | −12,035 | $1.83 | -$22.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ABOS Insider Holdings
16 insiders · @ $2.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rajeev M. Shah | Director | 19,103,785 | $40.12M | $350.00M | 4 | 2026-03-18 |
| 2 | Daniel Joseph OConnell | Chief Executive Officer | 881,275 | $1.85M | -$323.9K | 12 | 2026-01-23 |
| 3 | John A Stalfort III | Director | 352,219 | $739.7K | $560.0K | 7 | 2026-06-05 |
| 4 | Matt Zuga | CFO & Chief Business Officer | 304,924 | $640.3K | -$146.3K | 12 | 2026-01-23 |
| 5 | Eric Siemers | Chief Medical Officer | 255,371 | $536.3K | -$63.9K | 9 | 2026-01-23 |
| 6 | James J. Doherty | President and CDO | 220,900 | $463.9K | -$15.1K | 4 | 2026-01-21 |
| 7 | Russell Barton | Chief Operating Officer | 205,092 | $430.7K | -$59.4K | 10 | 2026-01-23 |
| 8 | Derek M Meisner | Chief Legal Officer & Corp Sec | 173,999 | $365.4K | -$305.9K | 13 | 2026-03-10 |
| 9 | Amy Schacterle | Chief Regulatory Officer | 92,303 | $193.8K | -$2.2K | 4 | 2026-01-21 |
| 10 | RA Capital Healthcare Fund LP | Director | 48,300 | $101.4K | $0 | 1 | 2026-06-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ABOS Proposed Insider Sales (Form 144)
Latest: 2026-06-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | DERRELL PORTER | Director | 13,040 | $30.3K | 2026-06-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-16 | DERRELL PORTER | Director | 12,800 | $29.8K | 2026-06-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-15 | DERRELL PORTER | Director | 6,460 | $15.1K | 2026-06-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-09 | NATHAN FOUNTAIN | Director | 6,400 | $14.3K | 2026-06-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-03-06 | Meisner Derek M | Officer | 2,090 | $6.7K | 2026-03-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-02-27 | Meisner Derek M | Officer | 9,406 | $28.3K | 2026-02-27 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-01-28 | Meisner Derek M | Officer | 2,671 | $8.0K | 2026-01-28 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-01-26 | Meisner Derek M | Officer | 15,085 | $45.3K | 2026-01-27 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-01-23 | Meisner Derek M | Officer | 5,633 | $10.5K | 2026-01-23 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-01-22 | Meisner Derek M | Officer | 1,054 | $1.9K | 2026-01-22 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 2.6 |
| EV/EBITDA | -1.2 |
| TTM Net Income | $-0.1B |
| TTM EPS | $-1.63 |
| ROE | -183.4% |
| Debt/Equity | 0.55 |